Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine. [electronic resource]
Producer: 20171213Description: 1 p. digitalISSN:- 1756-9966
- Antimetabolites, Antineoplastic -- pharmacology
- Carcinoma, Transitional Cell -- drug therapy
- Caspases -- metabolism
- Cell Cycle -- drug effects
- Cell Line, Tumor
- Cell Survival -- drug effects
- Checkpoint Kinase 1 -- genetics
- Checkpoint Kinase 2 -- genetics
- DNA Damage
- Deoxycytidine -- analogs & derivatives
- Drug Screening Assays, Antitumor
- Drug Synergism
- Gene Expression Regulation, Neoplastic -- drug effects
- Humans
- Poly(ADP-ribose) Polymerases -- metabolism
- Protein Kinase Inhibitors -- pharmacology
- RNA, Small Interfering
- Thiophenes -- pharmacology
- Urea -- analogs & derivatives
- Urinary Bladder Neoplasms -- drug therapy
- Gemcitabine
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.